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Gut microbiota provides the host with multiple functions (e.g., by contributing to
food digestion, vitamin supplementation, and defense against pathogenic strains) and
interacts with the host organism through both direct contact (e.g., through surface
antigens) and soluble molecules, which are produced by the microbial metabolism.
The existence of the so-called gut–brain axis of bi-directional communication between
the gastrointestinal tract and the central nervous system (CNS) also supports a
communication pathway between the gut microbiota and neural circuits of the host,
including the CNS. An increasing body of evidence has shown that gut microbiota is
able to modulate gut and brain functions, including the mood, cognitive functions, and
behavior of humans. Nonetheless, given the extreme complexity of this communication
network, its comprehension is still at its early stage. The present contribution will attempt
to provide a state-of-the art description of the mechanisms by which gut microbiota
can affect the gut–brain axis and the multiple cellular and molecular communication
circuits (i.e., neural, immune, and humoral). In this context, special attention will be paid
to the microbial strains that produce bioactive compounds and display ascertained
or potential probiotic activity. Several neuroactive molecules (e.g., catecholamines,
histamine, serotonin, and trace amines) will be considered, with special focus on
Glu and GABA circuits, receptors, and signaling. From the basic science viewpoint,
“microbial endocrinology” deals with those theories in which neurochemicals, produced
by both multicellular organisms and prokaryotes (e.g., serotonin, GABA, glutamate), are
considered as a common shared language that enables interkingdom communication.
With regards to its application, research in this area opens the way toward the possibility
of the future use of neuroactive molecule-producing probiotics as therapeutic agents for
the treatment of neurogastroenteric and/or psychiatric disorders.
Keywords: inter-kingdom communication, gut–brain axis, gut microbiota, enteric nervous system,
enteroendocrine cells, neuroactive molecules, mood, anxiety
COMMUNICATION SIGNALS THROUGH DIFFERENT
BIOLOGICAL KINGDOMS
Living organisms exchange information through systems that are based upon signal-receptor
interactions. The specific sense organs of higher animals have evolved to perceive signals, but
the whole living world, including protozoans, plants, fungi and bacteria, efficiently communicates
by exchanging information at a molecular level. Some universally sensed signals and widespread
receptors can be found in different kingdoms.
Frontiers in Microbiology | www.frontiersin.org 1 November 2016 | Volume 7 | Article 1934
fmicb-07-01934 November 28, 2016 Time: 12:6 # 2
Mazzoli and Pessione Microbial Glutamate and GABA Signaling
It has been suggested that ghrelin-like molecules, i.e.,
those structurally related to the appetite-stimulating lipopeptide
hormone which was first isolated from the gastrointestinal tract
of rats (Kojima et al., 1999), are ubiquitously present in living
organisms (Aydin et al., 2006). These molecules have been
found in microorganisms (i.e., viruses, archaea, and phototrophic
bacteria), animals and plants, where they fulfill different functions
(e.g., inhibition of apoptosis), especially those connected with
food intake and cell proliferation (Aydin, 2007). For instance, a
structural homolog (N-octanoyl homoserine lactone) of ghrelin
is produced by Gram-negative bacteria as a quorum sensing
(QS) autoinducer and cell-to-cell communication molecule,
which is also involved in food-searching (Aydin et al.,
2006).
Bacteria produce a huge range of compounds that are involved
in inter-microbial and host–microbe relationships. It is well-
known that QS peptides, once interpreted as specific bacteria–
bacteria communication signals (and regulating phenotypes such
as competence, sporulation, bioluminescence, biofilm formation,
bacteriocin/toxin production) also have metal (e.g., iron) binding
and antibiotic properties, that is, additional functions which
can promote the improvement of human health (Schertzer
et al., 2009). It has been established that antimicrobial pigments,
such as Serratia spp. prodigionines (active against fungal and
protozoan infections), can also control cancer and immunity
(Williamson et al., 2006). So, a single signal can be detected
by different cellular systems. “Dark side” examples also exist,
as in the case of farnesol, a QS-like molecule synthesized by
the yeast Candida albicans. Farnesol controls yeast/mycelium
transition, but also triggers the disruption of human erythrocytes,
and interferes with cytokine expression (Hornby et al., 2001;
Navarathna et al., 2007). The extremely long coevolution of host
and colonizing microbes can account for these inter-kingdom
effects.
The neurochemicals and their related receptors that are
found in mammals are far from being an exclusive to these
organisms, and are widely dispersed throughout nature, even in
microorganisms and plants that do not have nervous systems.
For instance, the stress-related neuro-endocrine hormone
family of catecholamines has also been demonstrated in fish,
insects, plants and bacteria (Lyte, 2011). Microorganisms
are able to produce a wide variety of neurochemicals. This
feature has been studied extensively by scientists engaged in
food safety, since the presence of neuroactive molecules in
food has been found to be responsible for cases of poisoning,
such as the “cheese reaction” and the “scombroid syndrome”
(related to food containing large amounts of tyramine and
histamine, respectively) (Pessione et al., 2005, 2009). It has
been suggested that at least some molecular neurotransmitters
and/or neuromodulators and/or neurohormones have been
conserved or shared during co-evolution as the “words” of a
common language, thus allowing communication between
phylogenetically very distant organisms (Lyte, 2011). It
has been hypothesized that such a common language
contributes to the homeostatic regulation of gut microbiota
and possibly to the functioning of the brain and behavior (Lyte,
2011).
MICROBIAL
NEURO-IMMUNO-ENDOCRINOLOGY:
HOW GUT MICROBIOTA AND THE HOST
CROSS-TALK
Microbial neuro-endocrinology is a branch of microbiology
which has recently arisen, and it refers to the bidirectional
communication that exists between commensal or parasite
microbiota and the host. Although, some reports refer to the
ability of bacteria to control the level of neurotransmitters
through Toll-like receptors (TLRs) and heat-shock proteins
(Sivamaruthi et al., 2015), this form of communication may occur
directly by means of neurochemicals.
The first evidence that bacteria could respond to mammalian
neuro-endocrine hormones dates back to 1929. These studies
reported the effect of neuro-hormones, and in particular
those belonging to the catecholamine family, on enhancing
the pathogenic phenotype of several bacterial strains, such as
Clostridium perfringens, during in vivo infections (Lyte, 2011).
At that time, these observations were interpreted to mean that
neurochemicals suppressed local immunity and thus favored the
rapid unimpeded growth of infectious microbes (Lyte, 2011).
However, evidence that prokaryotes can directly sense and
respond to neurochemicals (e.g., altering their growth and/or
virulence potential) has started to accumulate since the early
1990s. As an example, it is known that some intestinal molecules,
such as serotonin [5-hydroxy tryptamin (5-HT)], can modulate
the pathogenic potential of Pseudomonas fluorescens by affecting
its motility and pyoverdin production, but without affecting
its growth (Biaggini et al., 2015). Currently, this feature is not
considered rare, but is widespread over a high number of diverse
microorganisms (Lyte, 2011).
These findings have gained a great deal of attention in light of
the parallel emerging evidence of the so-called microbiota-gut-
brain axis, which allows bidirectional communication between
the gut microbiota and the central nervous system (CNS)
of animals, including humans (Cryan and Dinan, 2012).
It has been reported that gut microbiota can control the
tryptophan metabolism of the host by enhancing the fraction of
tryptophan available for the kynurenine route and decreasing the
amount available for 5-HT synthesis (O’Mahony et al., 2015).
These authors suggested that the deficiencies observed in the
serotonergic system of the elderly could be due to quantitative
and qualitative modifications of gut microbiota during aging
(O’Mahony et al., 2015). The cognitive and behavioral functions
of germ-free mice can be altered following colonization with
microbiota from a different mouse strain, and this can lead to a
similar increased exploratory behavior to that of the donor mouse
strain (Bercik et al., 2011b).
The observation of psychiatric co-morbidities in various
chronic inflammatory intestinal disorders has been interpreted
by some authors as further evidence of the influence of
gut microbiota on the CNS (Bercik et al., 2012; Cryan and
Dinan, 2012). Altered gut microbiota has been observed in
individuals affected by severe psychiatric disorders, such as
autism (Adams et al., 2011; Williams et al., 2011). Studies on
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animals infected by pathogenic bacteria, or treated with probiotic
or antibiotic agents have suggested that gut microbiota may
play a role in the genesis of multiple sclerosis, anxiety and
depression (Berer et al., 2011; Cryan and Dinan, 2012). However,
many psychiatric co-morbidities are thought to be the result
of perinatal infections, and should be interpreted within the
context of altered predisposition rather than microbiota-CNS
communication (Buka et al., 2008; Eßlinger et al., 2016; Gilman
et al., 2016). Since clear evidence of the role of gut microbiota in
the development of these syndromes is still lacking, this subject is
still the topic of debate.
However, all these reports have contributed to the concept
of the microbiota-gut-brain axis emerging as a “circular”
interactive network consisting of multiple (immune, neural, and
endocrine) interaction mechanisms. On one hand, the role of
the psychological status in the pathogenesis of/recovery from
infectious disease is recognized within the medical community
(Lyte, 2011). On the other hand, these studies have revolutionized
the traditional conception of human–microbiota relationships,
and hopefully opened fascinating perspectives as regards the
balancing of microbiota through the application of probiotics as
adjuvant agents in both neuro-enteric and psychiatric disorders
(Mazzoli, 2014). However, it should be pointed out that, due to
their extreme complexity and several confounding factors, the
understanding of the molecular mechanisms by which intestinal
microbiota can influence gut–brain communication or respond
to human-derived signals is still at its very beginning. And it is
also for this reason that the efficacy of probiotics as therapeutic
agents in psychiatric disorders is still a subject of massive debate
within the circle of experts (Bron et al., 2011; Kelly et al., 2015;
Santocchi et al., 2016).
The Gut–Brain Axis
The gut–brain axis defines a bidirectional communication system
that connects the GI tract with the CNS through multiple
pathways involving neural, endocrine, and immune cells. The gut
brain axis allows the CNS to regulate GI functions, including
motility and secretion, and the GI tract to signal sensations
such as hunger, pain, or discomfort to the CNS (Julio-Pieper
et al., 2013). However, new complex emotional (affective mood),
cognitive (memory formation) and behavioral functions (food
intake) are beginning to be discovered (Berntson et al., 2003),
and bacteria could play a role in this scenario (Cani and Knauf,
2016). Direct evidence that gut stimuli can affect emotional states
includes the fact that the intragastric infusion of fatty acids
in humans has been shown to reduce the brain response to
experimentally induced sad emotions (Van Oudenhove et al.,
2011).
The reciprocal influence between the GI tract and the CNS is
sustained by the enteric nervous system (ENS) (Furness, 2006;
Cryan and Dinan, 2012), which is considered as the third branch
of the autonomic nervous system and consists of about 200–
600 million neurons. Owing to its high number of neurons,
complexity, and similarity in signaling molecules with the brain,
ENS has also been referred to as the “second brain” (Gershon,
1998). ENS interfaces with the gut-associated lymphoid tissue
(GALT, which contains more than two-thirds of the body’s
immune cells) and with 1000s of entero-endocrine cells (EECs,
which contain more than 20 identified hormones). Furthermore,
the GI tract is directly innervated by the CNS through spinal
and vagal afferents (Mayer, 2011). For this reason, gut-to-brain
communications can occur through three main routes: (i) direct
perception of stimuli by primary afferent neurons (belonging to
the ENS or the CNS); (ii) immune system mediated connections;
(iii) EEC mediated connections.
Direct Neuronal Perception of Gut Chemical Stimuli
It is generally believed that the afferent terminals that innervate
the gut cannot sense luminal chemosignals directly, but can
through intermediate cells (e.g., EECs, immune cells) (Mayer,
2011). Under physiological conditions, protein-sized molecules
cannot pass the intestinal epithelium through the paracellular
pathway. However, lipophilic and small hydrophilic compounds
of up to 600 Da can cross the intestinal barrier through
multiple routes, e.g., through transcellular (namely, passive
diffusion into the lipid bilayer and/or small aqueous pores) and
paracellular routes (Keita and Söderholm, 2010). It can therefore
be hypothesized that small neuroactive compounds may also
use the latter pathways to diffuse in the lamina propria, that
is, in contact with intrinsic and/or extrinsic neural afferents, or
into the portal circulation, and therefore possibly exert extra-
intestinal effects. Some experimental evidence can in fact support
this hypothesis (Psichas et al., 2015). For instance, FFAR3
receptors for short chain fatty acids (SCFAs) have been detected
in submucosal and myenteric ganglia (Nøhr et al., 2013), and
the responsiveness of enteric neurons to glucose, amino acids
and fatty acids has been demonstrated (Liu et al., 1999; Furness
et al., 2013; Neunlist and Schemann, 2014). Furthermore, pattern
recognition receptors that are able to bind a variety of microbial
antigens have been identified in neural cells, including enteric
neurons, which could possibly enable a rapid activation without
the intermediation of immune cells (Lim et al., 2016) (for more
details, see Bacteria-Immune-Endocrine-Vagal Connections).
Neuroimmune Connections
About 70% of the body’s immune cells are present within the
GALT (Mayer, 2011). The existence of close connections between
afferent nerve terminals and immune cells (e.g., plasma cells,
eosinophils, and mast cells) within the gut mucosa has been
well-established (Keita and Söderholm, 2010; Mayer, 2011). For
example, the terminals of some vagal afferents can respond to
a variety of neuroactive compounds secreted by lymphocytes
and mast cells, such as histamine, 5-HT, prostaglandins and
various cytokines (Keita and Söderholm, 2010). Furthermore,
neuropeptide receptors have been identified in mast cells, thus
suggesting bi-directional communication between the nervous
and immune systems (Keita and Söderholm, 2010).
Neuro-endocrine Connections
Entero-endocrine cells account for less than 1% of epithelial cells
in the gut; nonetheless, they constitute the largest endocrine
organ of the body (Mayer, 2011). More than 20 different types
of EECs have been identified, and these differ according to
the type(s) of regulatory peptides (e.g., glucagon-like peptides,
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GLPs, pancreatic peptide YY, PYY, cholecystokinin, CCK,
secretin) or bioactive molecules that they secrete. EECs regulate
digestive functions through ENS circuits, and communicate
with the CNS (e.g., with the hypothalamus), either directly, i.e.,
through endocrine pathways, or through paracrine signaling to
vagal afferents (Raybould, 2010). Although, EECs and afferent
neurons have long been thought to communicate indirectly,
i.e., through neuropeptides released by EECs, a recent study
has also demonstrated direct synaptic contacts between EECs
and neurons (Bohórquez et al., 2015). Experimental evidence
has reported that suggests EECs could act as both pre-synaptic
(to communicate gut feelings to the nervous system) and post-
synaptic (e.g., for the possible modulation of the responsiveness
of EECs by efferent neurons) elements.
Immune-Endocrine Connections
Immune and enteroendocrine pathways are not distinct routes of
the gut–brain axis, but can influence each other to some extent.
Indeed, the release of interleukin-4 and 13 from CD4+ T cells, in
a mouse gut inflammation model has been reported to increase
cholecystokinin secretion in EECs (McDermott et al., 2006).
Enterochromaffin cells (ECs) have been described as being able to
modulate gut inflammation through 5-HT signaling (Mawe et al.,
2009).
Bacteria-Immune-Endocrine-Vagal
Connections
Studies in germ-free animals have underlined the importance
of gut microbiota in the early-life development of the gut–
brain axis, with particular reference to the hypothalamic-
pituitary-adrenal axis (Sudo et al., 2004). Pattern recognition
receptors such as TLRs, which are transmembrane proteins
that are able to recognize bacterial envelope components, such
as lipopolysaccharide (LPS) and lipoteichoic acids (Medzhitov,
2007), have been detected in a number of neuronal cells
which could potentially mediate the direct neuronal sensing
of microbial antigens (Lim et al., 2016). TLR4, which can be
activated by bacterial LPS, has been detected in the nodose
ganglion of the vagus nerve of rats (Hosoi et al., 2005). TLRs
3, 7, and 4 are expressed in the myenteric and submucosal
plexus of the murine intestine, the human ileum and the lower
dorsal root ganglia (Barajon et al., 2009). Similar results were
also obtained by Qi et al. (2011), who detected the expression
of TLRs 3, 7, and 9 in both human and murine dorsal root
ganglion neurons. High mRNA levels of TLRs 1, 4, 5, and 6
have been found in the colonic dorsal root ganglion neurons
of mice (Ochoa-Cortes et al., 2010). Furthermore, a number of
studies have reported the direct excitation of neurons by LPS
(Lim et al., 2016). However, in yet other studies the stimulation of
pattern recognition receptors of neurons did not cause any direct
excitation, but instead sensitized them and potentiated their
excitability (Lim et al., 2016). Nonetheless, these researches have
highlighted the existence of other possible pathways for bacteria
sensing and communication pathways between the nervous and
the immune systems.
Microbial exocellular polysaccharides (EPSs) are essential for
protecting bacteria from the host immune response, but also for
interacting with intestinal mucosal cells, including epithelial cells
and EECs, thus inducing the release of molecular messengers that
are able to modulate neural signaling or directly act on primary
afferent axons (Forsythe and Kunze, 2013).
Mucosal immune cells are able to distinguish commensal from
pathogenic bacteria (Artis, 2008) through TLRs, which are able
to detect microbial antigens. Similarly, dendritic immune cells
(extending their dendrites between epithelial cell tight junctions
so as to directly sense the luminal environment) and some
EECs can respond to the presence and activity of intraluminal
microbial organisms through TLRs (Mayer, 2011). The intestinal
infusion of Escherichia coli proteins has been reported to increase
the secretion of anorexigenic GLP-1 and PYY, thus providing
direct evidence of the ability of the gut microbiota to control
appetite (Tennoune et al., 2014; Breton et al., 2016). In addition,
EECs possess G-protein-coupled receptors that are able to
sense microbial metabolites, such as amino acids (for example
glutamate) (Bezençon et al., 2007), protein hydrolysates (Choi
et al., 2007) and both long and short fatty acids (Tanaka et al.,
2008; Nøhr et al., 2013). The expression of GPR41 receptor
of SCFAs has been detected in several types of EECs (e.g.,
those secreting CCK, ghrelin, gastrin, GLP-1, PYY, neurotensin,
secretin) throughout the GI tract of mice, from the stomach to
the colon (Nøhr et al., 2013). Both the GPR41 and 43 receptors
of SCFAs are expressed by enteroendocrine L-cells (Nøhr et al.,
2013). Their stimulation promotes the secretion of GLP-1 and
PYY (Samuel et al., 2008; Tolhurst et al., 2012; Nøhr et al., 2013).
Furthermore, gut microbiota indirectly regulates the release of
GLP-1, GLP-2 and PYY by modulating the differentiation of
stem cells into EECs, and thus modifying the number of GLPs
and PYY secreting L-cells (Everard et al., 2011). Another group
of gut microbiota metabolites, namely indole and tryptamine
derived from tryptophan, are known to modulate gut hormone
release. Indole triggers GLP-1 secretion by enteroendocrine
L-cells (Chimerel et al., 2014). Tryptamine induces ECs to secrete
5-HT (Takaki et al., 1985). Gut microbiota also contributes to
regulating sensitivity to leptin, the so-called “satiety hormone”
(Schéle et al., 2013).
Several microbial metabolites that display neuroactive
properties have been described: (i) gaseous molecules, such as
carbon monoxide, hydrogen sulfide and nitric oxide (Bienenstock
and Collins, 2010); (ii) SCFAs such as n-butyrate, propionate,
and acetate (Engelstoft et al., 2008; Nicholson et al., 2012);
(iii) amines, such as putrescine, spermidine, spermine and
cadaverine, which have been shown to be involved in CNS
responses to stress (Bienenstock and Collins, 2010).
Curiously, bacteria can produce a wide range of molecules
which mimic human hormones. For instance, muramyl dipeptide
(similar to serotonin) (Masek and Kadlec, 1983) and indole
(similar to melatonin) (Norris et al., 2013) can both cause sleep
and drowsiness, while LPS from Gram-negative bacteria can
directly act on thyroid cells, via type 4 TLRs, and up-regulate
thyroglobulin gene expression (Nicola et al., 2009).
On the other hand, the direct response of bacteria to
some of the regulatory peptides/neuroactive molecules that
are secreted by EECs and/or the human nervous system
has been demonstrated, which indicates the presence of
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neuromodulator/neurotrasmitter receptors in the bacterial
envelope (Lyte, 2011). For example, the stress hormones
epinephrine and norepinephrine increase the in vitro growth
of E. coli by more than four orders of magnitude (Freestone
et al., 2002) and the Clostridium/Bacteroides ratio in the human
gut (Bailey et al., 2011). A recent report has demonstrated that
Vibrio cholerae can respond to epinephrine and norepinephrine
(enhancing the growth rate, swimming motility, and production
of virulence factors such as iron sequestrating phenotype) by
means of specific sensor proteins (Halang et al., 2015).
Actually, the most forefront hypotheses consider that brain
and gut commensal bacteria communicate with each other
through shared chemical mediators, and this is part of the
homeostasis mechanisms that help to maintain gut microbiota
stability and possibly brain functions and behavior (Bienenstock
and Collins, 2010; Lyte, 2011). This neurochemical-mediated
“two-way street” (Figure 1) is one of the principles that supports
the microbial endocrinology construct (Lyte, 2011).
BACTERIAL PRODUCTION OF
NEUROACTIVE MOLECULES
The molecules that have assessed neuroactive properties
produced by bacteria are reported in Table 1. This list is far
from being exhaustive, and will likely include a progressively
higher number of strains and molecules as the results of a
greater number of studies become available. The bacteria that are
able to produce catecholamines include Bacillus spp. (producing
dopamine), Escherichia spp., and Bacillus spp. (producing
noradrenalin) (Lyte, 2011). The presence of the complete
biosynthetic pathway for catecholamines in these organisms has
raised the hypothesis that cell-to-cell signaling in vertebrates may
be the result of a late horizontal gene transfer from bacteria (Lyte,
2011).
Strains belonging to Streptococcus spp., Escherichia spp. and
lactic acid bacteria (LAB) are known to synthesize 5-HT (Lyte,
2011; Matur and Eraslan, 2012). It should be underlined that,
unlike what is generally believed, the gut (and not the brain) is the
main producer of 5-HT in mammals. The ECs of the gut mucosa
are the predominant site for the synthesis and storage of 5-HT in
humans (Gershon and Tack, 2007). The release of 5-HT occurs
in response to chemical stimuli, e.g., the presence of nutrients
(e.g., glutamate, glucose), or food-related/bacterial toxins in the
intestinal lumen (Mayer, 2011; Kitamura et al., 2012). However,
5-HT produced by gut microbiota could possibly contribute to
the overall 5-HT pool in the gut. It is known that 5-HT is involved
in the regulation of gut peristalsis, in vagal circuits associated with
nausea and vomiting and in the perception of visceral discomfort
and pain through spinal afferents (Costedio et al., 2007). For
these reasons, 5-HT has been the target of several treatments
of gastrointestinal and gut–brain associated disorders such as
inflammatory bowel disease, irritable bowel syndrome, post-
infectious irritable bowel syndrome, and idiopathic constipation
(Costedio et al., 2007).
Several LAB strains are able to synthesize β-phenylethylamine
and/or tyramine and/or tryptamine that belong to a group of
structurally related neuroactive compounds which are commonly
known as trace amines (Mazzoli, 2014). Trace amines (which
also include octopamine) are physiologically present in the
human nervous system, although in low amounts compared
to 5-HT and catecholamines, with which they display close
metabolic and neurophysiological relationships (Burchett and
Hicks, 2006). Tryptamine production has been detected in
Lactobacillus bulgaricus (Pessione et al., 2009), while Leuconostoc
and Enterococcus species have been reported to produce both
tyramine and β-phenylethylamine (Pessione et al., 2009). It is
worth noting that tryptophan decarboxylases have been found
in at least 10% of the samples tested from the NIH Human
Microbiome Project (Williams et al., 2014). Despite their low
amounts, trace amines, such as β-phenylethylamine, could play
a significant role as the co-transmitters and neuromodulators
(Burchett and Hicks, 2006) that are involved in mood
control, appetite/satiety circuits, and attention deficit/hyperactive
disorders (Shimazu and Miklya, 2004). Alterations in the trace
amine network also seem to be involved in psychiatric syndromes
such as bipolar disorder (BD), parkinsonism, and hepatic
encephalopathy (Burchett and Hicks, 2006).
Lactic acid bacteria and several other bacteria, such as those
that can contaminate fish or shellfish products, produce large
amounts of histamine, which is widely known as a mediator of
allergy and anaphylaxis but also plays a role as a neurotransmitter
in both the CNS and the ENS (Lyte, 2011).
Molecules that control QS communication between bacteria
(mainly peptides or acyl-homoserine lactones) have also been
shown to be involved in neuronal functioning (Hughes and
Sperandio, 2008).
Bacterial Production of Glutamate and
γ-Aminobutyric Acid (GABA)
L-Glutamate (Glu) and γ-aminobutyric acid (GABA) are mainly
known for their role as the main neuro-transmitters in
the mammalian CNS, with excitatory and inhibitory roles,
respectively (Hyland and Cryan, 2010; Julio-Pieper et al., 2013).
However, these molecules are widespread in nature and have
multiple functions, including plant signaling and communication
between bacteria (Dagorn et al., 2013).
Several bacterial strains are able to produce Glu. Coryneform
bacteria, such as Corynebacterium glutamicum, Brevibacterium
lactofermentum and Brevibacterium flavum, have been used
extensively for the industrial fermentative production of Glu
(Sano, 2009). LAB strains belonging to Lactobacillus plantarum,
Lactobacillus paracasei, and Lactococcus lactis are also able to
synthesize Glu (Tanous et al., 2005). A recent study has revealed
that about 15% of the LAB strains isolated from Asian fermented
foods are Glu producers (Zareian et al., 2012).
Both prokaryotes and eukarya synthesize GABA through
the decarboxylation of Glu by glutamate decarboxylase (GAD).
GAD has been found in both Gram-positive and Gram-negative
bacteria, where it is associated with systems that are involved
in pH homeostasis and the generation of metabolic energy (i.e.,
proton motive force) (Pessione, 2012; Tsai et al., 2013). Marine
microorganisms (Morse et al., 1980), E. coli (Richard and Foster,
2003) and Pseudomonas (Chou et al., 2008) can synthesize GABA.
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FIGURE 1 | The Microbiota-Gut–Brain Axis. Bi-directional communication between gut microbiota and the central nervous system (CNS) can occur through
either direct or indirect multiple pathways. These include endocrine, immune, and neural mechanisms (see text). Here, special focus is given to gut-to-brain
communication. 5-HT, serotonin; ACTH, adrenocorticotropic hormone; CRF, corticotropin-releasing factor; EC enterochromaffin cell; EEC, enteroendocrine cell; GI,
gastro-intestinal; IPAN; intrinsic primary afferent neuron; SCFAs, short-chain fatty acids (modified from Cryan and Dinan, 2012).
Among those microorganisms that are generally recognized as
safe or health-promoting, several LAB (e.g., strains belonging
to Lactobacillus, Lactococcus, and Streptococcus genera) and
Bifidobacterium strains have been reported to biosynthesize
GABA (Siragusa et al., 2007; Li and Cao, 2010; Mazzoli et al.,
2010; Lyte, 2011). Recently, one Lactobacillus strain and four
strains of Bifidobacterium isolated from the human intestine
have been reported to being able to produce GABA (Barrett
et al., 2012). Furthermore, a very recent analysis on metagenomic
data from the Human Microbiome Project suggests that genes
encoding GAD could be present in a significant proportion
of human gut microbiota (Pokusaeva et al., 2016). Lactobacilli
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TABLE 1 | Main neuroactive amines and amino acids released by bacteria.
Genus/species Bioactive molecule and
(precursor)
Physiological effects Reference
Lactobacillus spp., Enterococcus Histamine (His) Hypotension, allergies Pessione et al., 2005
Enterococcus faecalis Tyramine (Tyr) Hypertension, headaches Pessione et al., 2009
Enterococcus faecalis β-phenylethylamine (Phe) Appetite/satiety control, mood
control
Shimazu and Miklya, 2004
Bacillus Dopamine (Tyr) Multiple Lyte, 2011
Bacillus, Escherichia coli Nor-adrenaline (Tyr) Multiple Lyte, 2011
Bifidobacteria, LAB Melatonin (Trp) Smooth muscle relaxation,
Sleep/wake cycle regulator
Wong et al., 2015
Lactobacillus bulgaricus, Streptococcus, Escherichia
coli
Serotonin/triptamin (Trp) Vagal circuit regulation, peristalsis Matur and Eraslan, 2012
Corynebacterium glutamycum, Lactobacillus
plantarum, Lactobacillus paracasei, Lactococcus lactis
Glu Multiple Tanous et al., 2005; Sano, 2009;
Zareian et al., 2012
LAB, Escherichia coli, Pseudomonas GABA (Glu) Anxiolytic, miorelaxant Richard and Foster, 2003; Chou
et al., 2008; Mazzoli et al., 2010
include the strains with the highest GABA production, although
this metabolic ability is more likely strain- rather than genus-
related (Li and Cao, 2010).
Glu/GABA: RECEPTORS, SIGNALING,
AND TRANSPORT
Bacterial Targets: Glu and GABA
Receptors in Prokaryotes
The role of GABA in the communication between bacteria is in
line with the identification of GABA-binding proteins in different
prokaryotes. These proteins consist not only of transporters,
such as GabP in E. coli or Bacillus subtilis) (Brechtel and King,
1998; Hu and King, 1998) and Bra in Agrobacterium tumefaciens
(Chevrot et al., 2006), but also of possible specific receptors
(Guthrie and Nicholson-Guthrie, 1989). It has been reported
that metabotropic Glu and GABAB receptors, as well as bacterial
periplasmic amino acid binding proteins, may have evolved from
a common ancestor (Cao et al., 2009). In addition, as reported in
the previous section, many bacteria (including those colonizing
the human gut) can synthesize GABA, thus suggesting that, as
in the case of eukaryotes, GABA might be a conserved and
ubiquitous communication molecule.
The fact that GABA has an effect on the physiology
of Pseudomonas can be supported by several observations.
A periplasmic protein showing high affinity for GABA and
displaying similar biochemical features to a subunit of the
mammalian GABAA ionotropic receptor was identified in an
environmental strain of P. fluorescens (Guthrie and Nicholson-
Guthrie, 1989; Guthrie et al., 2000). Specific receptors for sensing
GABA have been found in other Pseudomonads including:
the PctC of P. aeruginosa and the McpG of P. putida, which
are involved in GABA chemoreception (Reyes-Darias et al.,
2015). Another study has demonstrated that GABA increases
the cytotoxicity and virulence of P. aeruginosa through a
sophisticated modulation of the protein expression (Dagorn et al.,
2013). A functional proteomic analysis revealed that six proteins
were differentially expressed in P. aeruginosa when exposed to
GABA (Lyte, 2011). Hence, some bacteria are able to respond to
GABA, of both prokaryote and mammalian origin.
A structurally similar ion channel to eukaryotic ionotropic
GABAA receptors was identified in the plant pathogen Erwinia
chrysanthemi (Zimmermann and Dutzler, 2011). The prokaryotic
protein is activated by different amines, including GABA, and
is modulated by benzodiazepines in a similar manner to its
eukaryotic homolog (Zimmermann and Dutzler, 2011; Spurny
et al., 2012).
Less information is available on prokaryotic Glu receptors. As
far as we know, only a single case of a Glu-activated potassium
channel in a bacterium (i.e., GluR0 from Synechocystis PCC 6803)
has been reported to date (Chen et al., 1999). However, 100
prokaryotic channel proteins with putative Glu binding domains
have recently been identified through a bioinformatic study (Ger
et al., 2010). Among them, 22 proteins have been found to be
homologs of vertebrate ionotropic Glu receptors (Ger et al.,
2010).
Based on these findings, it is possible to hypothesize that
members of the human gut microbiota can also sense and
respond to GABA/Glu, although this has yet to be confirmed
through dedicated studies. Furthermore, human-derived or
dietary Glu can affect the balance of gut microbial populations by
stimulating the growth of certain bacterial species at the expense
of others. It is known, for instance, that LAB decarboxylate Glu
to GABA in order to create a protonic gradient and enhance
metabolic energy. Hence, Glu can constitute a privileged energy
source that can be used to expand LAB populations.
Host-Targets: the
Glutamatergic/GABAergic System in the
CNS
Glu and GABA are the major excitatory and inhibitory
neurotransmitters found in the human CNS, respectively (Julio-
Pieper et al., 2013). These compounds are the molecular effectors
of a homeostatic neuronal circuit that is characterized by extreme
complexity and sophistication at both a physiological and a
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FIGURE 2 | (A) Representation of a Glutamatergic/GABAergic neural network, including an excitatory (Glutamatergic) pyramidal neuron (red), inhibitory (GABAergic)
neurons (blue) and the related connections. The inhibitory neuron on the left is integrated into a feedback (FB) circuit, while the inhibitory neuron on the right is
integrated into a feed-forward (FF) loop. Inhibitory synapses targeted to the soma or dendrites of the pyramidal cell are surrounded by light blue staining, which
indicates a background GABA concentration that contributes to the overall inhibition (adapted from Roth and Draguhn, 2012). (B) Scheme of the
Glutamatergic/GABAergic neurotransmission in the CNS. α-KG, α-keto-glutarate; EEATs, excitatory amino acid transporters; GABA, γ-aminobutyric acid; GABAA-R,
GABAA receptor; GABAB-R, GABAB receptor; GABAC-R, GABAC receptor; GABA-T, GABA transaminase; GAD, Glu decarboxylase; GAT-1, GABA transporter 1;
GlnT, glutamine transporter; Glu, glutamate; iGluR, ionotropic Glu receptor; mGluR, metabotropic Glu receptor; SSAl, succinic semialdehyde; SSAlDH, succinic
semialdehyde dehydrogenase; TCA cycle, the Krebs cycle; vGAT, vesicular GABA transporter; vGluT, vesicular Glu transporter. Symbols:  , GABA; N, Glu.
biochemical level. This system also includes glutamine (Gln),
which plays a key role as a non-neuroactive intermediate in the
recycling of neurotrasmitters in the brain, mainly Glu and GABA
(Soeiro-de-Souza et al., 2015).
At a physiological level, this network consists of feed forward
(FF) and feedback (FB) neuronal connections in which the
main role of inhibitory (i.e., GABAergic) neurons is currently
considered as that of balancing the activity of excitatory (i.e.,
Glutamatergic) neurons (Roth and Draguhn, 2012; Figure 2A).
Both Glutamatergic and GABAergic neurotransmissions are
complex systems in which glial cells (mainly astrocytes), pre- and
post-synaptic neurons and a large spectrum of different receptors,
transporters and enzymes are involved (Cherlyn et al., 2010;
Femenía et al., 2012; Figure 2B).
The biochemical relationship between Glu and GABA goes
far beyond this reciprocally modulating activity, since Glu
and GABA are easily interconverted. Actually, the biochemical
reactions involved in GABA-to-Glu-to-Gln conversion are
integral features of such a regulatory network, which also involves
the central energy metabolism of neurons (Soeiro-de-Souza et al.,
2015; Figure 2B).
Glu is synthesized in situ in the CNS since it cannot pass
the blood–brain barrier (BBB) (Hawkins, 2009). One of the
main Glu biosynthetic pathways consists of the conversion
of glucose (through the Embden-Meyerhof-Parnas pathway
and the Krebs cycle) to α-ketoglutarate (α-KG), which is
subsequently transaminated (Cherlyn et al., 2010). Glu is
accumulated in vesicles and, after suitable stimulation, released
to the synaptic space, where it can bind to a panel of Glu
receptors (GluRs) that may be found in post-synaptic neurons.
GluRs differ on the basis of their mechanism of action (e.g.,
ionotropic, iGluR, or metabotropic, mGluR, Glu receptors)
and pharmacological responsiveness [e.g., N-methyl D-aspartate,
NMDA, or α-amino-3-hydroxy-5-methylisoxazole-4-proprinoic
acid (AMPA) or kainate sensitive receptors]. Ligand-gated
ionotropic receptors mediate fast synaptic responses by directly
regulating the ion influx. Metabotropic receptors are coupled
to G-proteins and modulate slower signal transduction cascades
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(Hyland and Cryan, 2010; Julio-Pieper et al., 2013). Any excess
Glu present in the synaptic cleft is taken up by glial cells or
neurons to prevent the prolonged excitation of post-synaptic
neurons, which can lead to cell death (Cherlyn et al., 2010). Glu
in the glia is either oxidatively deaminated to α-KG [by Glu
dehydrogenase (GluDH)], or converted to Gln by Gln synthetase.
Gln is released from glial cells, uptaken by pre-synaptic neurons
[via Gln transporters (GlnT)], and is then converted back to
Glu by glutaminase. Apart from its role in neurotransmission,
Glu is also involved in other neural processes, such as neuronal
development and synaptic plasticity (Cherlyn et al., 2010).
Inhibitory pre-synaptic neurons convert Glu to GABA
through GAD and pack it into vesicles via vesicular GABA
transporters (vGATs). Again in this case, Gln is an alternative
Glu source to α-KG. The multiple GABA receptors that are
present in post-synaptic neurons include ionotropic (GABAA,
GABAC) and metabotropic (GABAB) receptors. Apart from
GABA, these receptors are possibly modulated by a number of
other compounds, e.g., barbiturates, baclofen, benzodiazepines
and steroids (Simeone et al., 2003; Goetz et al., 2007).
Any excess unbound GABA is cleared by glial cells through
GABA transporters (GAT-1). GABA is then converted by
GABA transaminase (GABA-T) into succinic semialdehyde, with
concomitant Glu biosynthesis (Sivilotti and Nistri, 1991; Michels
and Moss, 2007).
Glu/GABA: From the Gut to the Brain
As described above, several bacteria, including probiotic bacteria
and bacteria that colonize the human GI tract, are able to produce
Glu or GABA (Barrett et al., 2012). As far as we know, only one
study concerning the modulation of host Glutamate/GABAergic
systems by GABA/Glu producing gut-colonizing bacteria is
available in the literature (Bravo et al., 2011). A recent study has
demonstrated that a GABA-producing Bifidobacterium dentium
is able to attenuate sensitivity of dorsal root ganglia neurons
in a rat model of visceral pain (Pokusaeva et al., 2016). It
is worth noting that these few examples refer to the limited
number of studies on interaction between gut microbiota and the
host nervous system which is currently available. Experimental
evidence is likely to grow as a higher number of reports become
available. To date, most studies on the Glu/GABA effects on
humans concern dietary Glu/GABA.
Glu and GABA can be found in food as natural components
or as food supplements. Glu is among the most abundant
amino acids (8–10%) found in dietary proteins. Furthermore,
monosodium glutamate is employed extensively as a flavor
additive in food (Brosnan et al., 2014). In Germany, Glu average
intake (comprinsing both free Glu and Glu as protein constituent
in foods) of about 10 g/day has been estimated (Beyreuther et al.,
2007). In asian consumers this value is likely higher since free
Glu intake can reach up to 4 g/day in these countries (Beyreuther
et al., 2007). GABA is relatively abundant in plant food, such as
brown rice germs and sprouts, spinach, barley and bean sprouts,
where GABA concentrations of between 300 and 720 nmol/g
dry weight have been detected (Oh et al., 2003), while higher
levels are found in fermented foods (Abdou et al., 2006). In
recent years, the utilization of GABA as a food supplement has
progressively increased in both Asian and Western (USA and
Europe) countries (Boonstra et al., 2015). GABA concentration
of few micrograms per gram of cecal content has been detected in
mice (Pokusaeva et al., 2016).
Hundreds of people have reported the benefits of using GABA-
supplemented food, for instance in alleviating anxiety and/or
improving sleep quality (Boonstra et al., 2015). Moreover, at least
five different studies have reported that the oral administration of
GABA or GABA-supplemented food/beverages (corresponding
GABA amounts of about 50–100 mg) has had positive effects
on human health. These effects include: (i) the reduction of
psychological stress in people who performed arithmetic tasks
(Nakamura et al., 2009; Kanehira et al., 2011; Yoto et al., 2012);
(ii) the reduction of stress in acrophobic subjects exposed to
heights (Abdou et al., 2006); (iii) an increased ability to perform
prioritized planned actions (Steenbergen et al., 2015).
Multiple pathways by which gut luminal Glu/GABA may
affect the CNS can be hypothesized, including their transport
across intestinal and BBB and their sensing through afferent
terminals that innervate the GI tract (Figure 3). In the next
sections, evidence possibly supporting these mechanisms will be
illustrated.
Direct Influence of the Luminal Glu/GABA in the Gut
on the CNS
Multiple transporters that mediate Glu absorption have been
found in the apical membrane of GI epithelial cells, mainly in
the small intestine, but also in the stomach (Burrin and Stoll,
2009), while little or no transport of amino acids from the
lumen to portal blood occurs in the colon (Julio-Pieper et al.,
2013). Studies on pigs and rodents have indicated the excitatory
amino acid carrier 1 is the most abundant Glu transporter in the
mucosa of the small intestine (Burrin and Stoll, 2009). A study
performed in infant pigs has indicated that rate of Glu absorption
and transport to the portal circulation linearly increases with
increasing intraduodenal Glu intake (Janeczko et al., 2007).
Portal absorption rate increased from 3.80 µmol kg−1 h−1for
normal Glu intake (i.e., 510 µmol kg−1 h−1) to 20.46
3.80 µmol kg−1 h−1 for piglets infused with 3.5-fold increased
Glu intake (Janeczko et al., 2007). Glu is one of the main
nutrients for enterocytes. Several studies on different animal
models, including pre-term infants and human adults, have
agreed on that most Glu present in the GI lumen is oxidized
to CO2 or, secondarily, converted to other amino acids by the
gut mucosa (Burrin and Stoll, 2009). Only a small percentage
(between 5 and 17%, depending on the studies) of the ingested
Glu is transported into the portal circulation but this does not
generally affect the Glu concentration in the plasma to any great
extent (Hays et al., 2007; Brosnan et al., 2014). Furthermore,
an increased plasma Glu concentration (following Glu intake)
does not necessarily affect the Glu concentration in brain tissues,
since it is generally recognized that Glu cannot pass the BBB
(Janeczko et al., 2007). A 20-fold (or more) increase in plasma
Glu concentration was found necessary to access the brain tissues
in rodents (Brosnan et al., 2014). The reaching of such a high Glu
concentration in plasma after dietary intake (or Glu biosynthesis
by gut microbiota) seems rather unlikely.
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FIGURE 3 | Potential pathways for luminal Glu/GABA in the gut (of either dietary or gut–microbiota origin) to influence the nervous system (see text).
5-HT, serotonin; EC enterochromaffin cell; EEC, enteroendocrine cell; GI, gastro-intestinal; IPAN; intrinsic primary afferent neuron (from Cryan and
Dinan, 2012).
As far as GABA transporters are concerned, they are
mostly found in the CNS (Gadea and López-Colomé, 2001).
However, H+/GABA symport across the apical membrane of
human intestinal epithelial (Caco-2) cells has been demonstrated
(Thwaites et al., 2000). In fact, the hPAT1 H+/amino acid
symporter, which is thought to mediate the uptake of luminal
GABA, is present throughout the human GI tract, from the
stomach to the discending colon, with maximal expression in
the small intestine (Chen et al., 2003). Furthermore, GABA
carriers have been detected in the basolateral membrane of
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Caco-2 cells (Nielsen et al., 2012). These findings suggest that
luminal GABA should be able to cross the intestinal barrier and
possibly reach extra-intestinal targets. In fact, orally administered
GABA in rats was reported to increased GABA concentration
in their blood, with a peak after 30 min (Abdou et al., 2006).
Nonetheless, GABA ability to cross the BBB is still controversial
(Boonstra et al., 2015). Most early studies, performed between
1950 and 1980, agreed on the impermeability of BBB to GABA,
but more recent investigations have reported that GABA may
actually cross this barrier, although in small amounts (Boonstra
et al., 2015). These discrepancies have been ascribed to the
different method of administration (e.g., oral versus injection),
or animal model employed. Some studies have also suggested
that BBB permeability to GABA could diminish with increasing
age (Boonstra et al., 2015). Interestingly, GABA-transporters
have been found in the BBB of mice (Kakee et al., 2001).
Direct evidence of GABA facilitated transport across the BBB
of mice has been reported, although the efflux rate from the
brain was 17 times higher than the influx rate (Kakee et al.,
2001). Unfortunately, no information about the possible presence
of similar transporters in the BBB of humans is currently
available.
All together, these findings suggest that a direct action of
luminal gut Glu and/or GABA on the CNS cannot be excluded,
although further in vivo studies are required to confirm this
hypothesis. These investigations should also take into account
that gut and/or BBB permeability are affected by several factors,
including stress, diet and gut microbiota (Braniste et al., 2014;
Kelly et al., 2015).
Sensing of Luminal Glu/GABA in the Gut
Multiple Glu receptor types (including ionotropic, types 1 and 4
metabotropic receptors and heterodimeric, TAS1R1 + TAS1R3,
L-Glu taste receptors) have been detected in GI epithelial cells
and/or enteric neurons in the stomach, small intestine and colon
(Kondoh et al., 2009; San Gabriel et al., 2009; Kitamura et al.,
2012). More in detail, mGlu4 receptors have been detected in
the mucosa of both the gastric antrum and duodenum (Akiba
et al., 2009), while both mGlu4 and mGlu7 receptors have been
identified in the colon epithelium (Chang et al., 2005; Julio-Pieper
et al., 2010). TAS1R3, a subunit of umami taste receptors, has
been found in enteroendocrine L-cells and X/A-like cells (Jang
et al., 2007; Hass et al., 2010). This evidence suggests a possible
role in luminal Glu sensing. In fact, small intestine luminal L-
Glu seems to play a role in the defense mechanisms of duodenal
mucosa in rats, by increasing the intracellular pH and mucus
gel thickness (Akiba et al., 2009). A role of mGluRs in the
human colon in the control of colon peristalsis and electrolyte
transport has been described (Julio-Pieper et al., 2013). High
levels of mGlu7 and mGlu8 have been detected in myenteric
neurons, where they are possibly involved in the regulation of
gut motility (Julio-Pieper et al., 2013). However, results on the
ability of gut luminal Glu to directly excite enteric neurons still
appear contradictory (Kirchgessner, 2001; Wang et al., 2014).
On the other hand, an indirect activation of vagal afferents
(i.e., via the production and release of nitric oxide and 5-HT)
through the administration of Glu to the gastric lumen has been
demonstrated (Uneyama et al., 2006). These data strongly suggest
a role of ECs in the mediation of luminal Glu sensing. This
luminal Glu sensing mechanism stimulates different areas in the
CNS, including the cerebral cortex, basal ganglia, limbic system,
and hypothalamus (for a comprehensive review, refer to Kondoh
et al., 2009), and induces flavor preference in rats (Kitamura et al.,
2012).
GABAB receptors are abundantly expressed in the GI tract
(Hyland and Cryan, 2010). GABA and its ionotropic and
metabotropic receptors are widely distributed throughout the
ENS, in both submucosal and myenteric neurons, from the
stomach to the ileum (Auteri et al., 2015). In addition,
Nakajima et al. (1996) reported the expression of GABAB
receptors in cells morphologically similar to EECs, where
they co-localized with cells containing somatostatin (in the
stomach) or serotonin (in the duodenum). However, a later
study failed to detect any positive EEC for GABAB receptors
(Casanova et al., 2009). Schwörer et al. (1989) showed
that the release of 5-HT by ECs in the small intestine of
guinea-pig is modulated by GABAA and GABAB receptors.
Involvement of GABAB receptors in modulation of sensitivity
of vagal and spinal afferents has been reported (Hyland and
Cryan, 2010). Actually, the GABAB metabotropic receptors
in the GI tract are thought to regulate several functions,
including gut motility and gut-to-brain signaling (Hyland
and Cryan, 2010). Experimental evidence of GABAB/µ-type
opiod receptor interaction, which mediates the synergistic
potentiation of the anti-nociceptive action of GABA/morphine
co-administration, has been reported (Hara et al., 1999). A similar
GABAB receptor-mediated potentiation effect has also been
described for drugs used to reduce visceral pain (Hara et al.,
2004).
Since GABA receptors have been found in a wide range
of immune cells, such as dendritic cells, mast cells and
T-cells (Auteri et al., 2015), and are involved in regulating
immunological processes, such as the down-regulation of pro-
inflammatory cytokine release (Bjurstöm et al., 2008), their role
in neuro-immune dialog in the gut has been proposed (Auteri
et al., 2015).
It is worth reminding that GABA is produced through Glu
decarboxylation in both eukarya and prokaryotes. Hence, GABA-
producing microorganisms that are present in the gut may
significantly affect luminal Glu/GABA ratio and, therefore, gut
signaling.
PROBIOTICS FOR THE TREATMENT OF
PSYCHIATRIC DISORDERS?
As far as its application to the field of probiotics is concerned,
microbial neuro-endocrinology addresses the ability of probiotics
to both synthesize and respond to neuroactive compounds, and
thus to affect the host neurological processes and sometimes the
overall physiology of the host. A microbial endocrinology-based
approach may be relevant to help understand how probiotics can
influence the health of a host and how host can select commensal
microbial populations.
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A number of studies have provided evidence on the
ability of probiotic strains to modulate the mood and stress
responses of humans, and to reduce anxiety and depression
(Logan and Katzman, 2005; Messaoudi et al., 2011; Arseneault-
Breard et al., 2012). As an example, the administration of
Bifidobacteria and LAB as probiotic supplements to humans
can increase the levels of morning salivary melatonin, thus
reducing the symptoms of irritable bowel syndrome (Wong et al.,
2015). Actually, most of the currently recognized probiotic strains
belong to Bifidobacteria and LAB, with lactobacilli being among
the most abundant members of such health-promoting strains
(Vaughan et al., 2011). A direct modulation of myenteric neuron
activity by unidentified Bifidobacterium longum fermentation
product(s) displaying anxiolytic effects has also been reported
(Bercik et al., 2011a).
Alterations in the Glu/ Gln/ GABA circuits in the CNS
have been reported for generalized anxiety disorders, as well as
in other psychiatric conditions, such as the major depressive
disorder (MDD), BD (also known as manic depressive disorder)
and schizophrenia (SZ) (Cherlyn et al., 2010; Femenía et al.,
2012; Soeiro-de-Souza et al., 2015). It is worth noting that
these complex neurobehavioral disorders affect a significant
portion of the overall population throughout the world (e.g.,
individuals affected by BD or SZ account for about 2–3% of
the global population) (Cherlyn et al., 2010). Different classes
of drugs addressed to different steps of Glutamate/GABA-
ergic neurotransmission (e.g., reducing Glu release, increasing
Glu re-uptake, or increasing GABA levels by enhancing GAD
or inhibiting GABA transaminase and succinic semialdehyde
dehydrogenase) or serendipitously discovered (e.g., valproic
acid) have been used in the treatment of such mood disorders
(Terbach and Williams, 2009; Femenía et al., 2012). However,
drugs frequently have negative secondary effects. For instance,
most antidepressants (such as tricyclic antidepressants), while
having a positive effect on the mood of humans, do not
alleviate and can even aggravate cognitive symptoms, or
impair vigilance (e.g., selective 5-HT reuptake inhibitors),
and may cause dependence (e.g., benzodiazepines) (Femenía
et al., 2012). Finding alternative or adjuvant therapies is
therefore a research priority and, in this respect, the use
of neuromodulating bacteria or so-called psychobiotics is a
fascinating perspective.
Interestingly, the anxiolytic and anti-depressant-like effects
of Lactobacillus rhamnosus JB-1 ingestion in mice involve a
reduction in the plasma corticosterone levels and alterations
of both GABAA and GABAB receptor expression patterns
in specific brain areas (Bravo et al., 2011). Furthermore,
increases in the Glx (i.e., Glu + Gln) and GABA levels
in the CNS have been observed after 2 and 4 weeks of
L. rhamnosus JB-1 treatment, respectively (Janik et al., 2016).
These effects were mediated by gut-to-brain communication
through the vagus nerve (Bravo et al., 2011). However, whether
L. rhamnosus stimulates the vagus nerve with its own GABA
or induces an endogenous GABA production still has to be
clarified.
Modulation of the glutamatergic system in the central
amygdala, cortex and hippocampus of mice by gut microbiota
has been described (Sudo et al., 2004; Neufeld et al.,
2011).
Although, GABA production has been speculated as the key
factor in the ability of a Lactobacillus helveticus–B. longum
mixture to reduce anxiety-like behavior(s) (Lyte, 2011), the
observed probiotic effects on the psychological health of a host
are generally likely the result of multiple interactions with the
host (ENS, EEC, GALT). On the other hand, anorexigenic and
anxiolytic soymorphin peptides (produced by LAB proteolytic
action toward soy betaconglycinine) act via the GABAB receptor
and, in this overall action, multiple circuits (including 5-HT and
dopamine receptors) are involved (Kaneko et al., 2010). A recent
investigation have suggested that a GABA-producing B. dentium
is able to reduce nociception in a rat model of visceral pain
(Pokusaeva et al., 2016).
Because of the wide range of potential neuro-active
compounds (orexant, anorexant, opioid, opioid antagonist)
produced by bacteria and the complex network that exists
between them, a deep characterization of the proteome and
metabolome of probiotic strains is one key aspect that would
help to understand the different effects exerted by each strain
on human health. Since not only Glu/GABA receptors but
also other circuits can be potential targets for bacterial-derived
molecules, it is tempting to hypothesize the use of probiotics
that produce bioactive compounds (e.g., GABA, 5-HT, opioid
peptides) as a novel frontline strategy for the adjuvant treatment
of gastrointestinal, neuroenteric, neurological and psychiatric
conditions (Hyland and Cryan, 2010; Lyte, 2011; Reid, 2011).
Together with this optimistic viewpoint and the enthusiasm
that these findings have generated in the scientific domain,
it is worth stating that a number of issues suggests caution
in application of psychobiotics. The comprehension of the
mechanisms by which gut microbiota and the nervous system
communicate is still at its beginning. Multiple levels of
complexity hinder the detailed understanding of this network and
these include (but are not limited to) the fact that: the gut–brain
axis comprises multiple (i.e., neural, immune, and endocrine)
pathways with several reciprocal interactions; multiple molecular
mediators, such as GABA and Glu, are involved, which play roles
in a number of different biological processes; gut microbiota
and even single commensal microorganisms interact with
the host through multiple pathways and chemical mediators
(e.g., cell envelope components, production/metabolism of
neurotransmitters or neuroactive molecules). Therefore, it may
be difficult to specifically address health problems with such
microbial agents without the risk of unbalancing other pathways.
As for other potential therapeutic agents, rigorous evaluation of
the potential beneficial effects together with possible negative
side effects should be performed for each probiotic/psychobiotic
agent.
CONCLUSION
The increasing knowledge about gut bacteria–brain bi-
directional communication has provided scientific evidence
that can explain the popular statement that somebody has
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made a decision based his/her on gut feeling, but also the
saying “we are what we eat,” as it is supposed that diet can
affect the microbiota composition of the gut. It is now evident
that gut microbiota is able to interfere, through its cellular
components or by secreting bioactive compounds, with the gut–
brain axis through immune, neural and humoral pathways.
As the knowledge of this domain increases, new unexpected
and exciting perspectives for both basic and applied science
will likely emerge. At the same time, the observed effects
of human-derived neuro-active compounds on gut microbiota
would seem to suggest that some neurochemicals share a
common language that enables interkingdom communication,
as proposed by Lyte and Freestone (2010). The ability of
a microbial strain to affect the overall patho-physiology
of a host thus appears to be the result of a long and
sophisticated synergic evolution between gut bacteria and the
host.
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